The fact that we investigated the prevalence of only 2 specific founder mutations is the major limitation of our study; however, according to the already published data, these 2 founder mutations account for more than 80% of all the BRCA1 mutations that were found among the cancer patients in Latvia [8,9]. This evidence concerns the gene BRCA1 and cancer.